Browse News
Filter News
Found 833 articles
-
Liquid Biopsy Industry is Rising Rapidly Up to USD 32.54 Bn by 2033
4/19/2024
The global liquid biopsy market size was valued at USD 10.85 billion in 2023 and is projected to reach USD 32.54 billion by 2033, growing at a CAGR of 11.61% from 2024 to 2033 according to a new report by Nova One Advisor.
-
Renovaro Inc. Proudly Announces the Appointment Of Professor Dr. Geert Kazemier as the Chairman of its Scientific Advisory Board
4/18/2024
Renovaro Inc., a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, announces the distinguished Professor Geert Kazemier, MD, PhD, as the new Chairman of its Scientific Advisory Board.
-
Epigenetic Laboratories Partner to Increase Access to Early Cancer Detection Technology, as U.S. Braces for Record High New Cancer Cases
4/12/2024
As health officials in the United States brace for an all-time record high of new cancer cases in 2024, the demand for access to novel cancer screening technologies sees an urgent spike.
-
Nodexus Adds Flow Cytometry Leaders to Scientific Advisory Board
4/10/2024
Nodexus Inc. today announced that three leading experts in cytometry sciences, pathology, and cancer biology have joined its Scientific Advisory Board (SAB).
-
Telo Genomics Receives Accreditation from College of American Pathologists
4/10/2024
"Telo Genomics demonstrates leadership, innovation, and a passionate commitment to standards of excellence while providing the highest quality services, ultimately for patients," said Richard M. Scanlan, MD, FCAP, chair of the CAP's Council on Accreditation
-
Omega Therapeutics Presents New Preclinical Data at AACR 2024 Supporting the Potential of Precision Epigenomic Control
4/9/2024
Omega Therapeutics, Inc. today announced the presentation of new preclinical data demonstrating the anti-tumor effect of a MYC-targeting epigenomic controller (MYC-EC) in models of EGFR inhibitor (EGFRi)-resistant non-small cell lung cancer (NSCLC) at the American Association for Cancer Research Annual Meeting 2024, taking place in San Diego, California, April 5 – 10.
-
QIAGEN strengthens its portfolio for cancer research, showcasing latest product launches at AACR Annual Meeting 2024
4/3/2024
QIAGEN N.V. announced a series of new products to further enhance cancer research as well as to enable urine collection and stabilization as a new approach for liquid biopsy.
-
Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting
4/3/2024
Guardant Health, Inc. today announced it will present data from nine studies highlighting advances in methylation-based epigenomic analysis for precision oncology at the 2024 American Association for Cancer Research (AACR) Annual Meeting, April 5-10 in San Diego.
-
Telo Genomics' Flagship MRD Clinical Trial Expands into Multi-Center Trial
4/2/2024
Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications
-
Tellbio’s Technology Demonstrates that Analysis of Circulating Tumor Cells Can Predict Survival Among Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Radium-2230
3/27/2024
TellBio, Inc., a development-stage medical technology company focused on revolutionizing the detection of cancer metastasis through its unique and proprietary circulating tumor cell (CTC) technology, the TellDx CTC System, announces the publication of data that shows the promise of CTCs as a prognostic biomarker for patients with prostate cancer receiving novel therapies such as radium-223.
-
UPDATE – Tellbio’s Technology Demonstrates that Analysis of Circulating Tumor Cells Can Predict Survival Among Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Radium-223
3/27/2024
TellBio, Inc. announces the publication of data that shows the promise of CTCs as a prognostic biomarker for patients with prostate cancer receiving novel therapies such as radium-223.
-
Revolutionary Evotip Workflow Enables Unprecedented Proteomic Analysis
3/20/2024
Evosep, a leading provider of sample preparation and separation solutions for mass spectrometry-based proteomics, is thrilled to announce the publication of a groundbreaking study in Nature Communications highlighting the capabilities of its innovative Evotip technology.
-
Omega Therapeutics Announces Two Poster Presentations at the American Association for Cancer Research Annual Meeting 2024
3/6/2024
Omega Therapeutics, Inc. announced that it will present two posters at the American Association for Cancer Research Annual Meeting 2024, taking place in San Diego, California, April 5 – 10, 2024.
-
Telo Genomics Initiates MRD Clinical Trial for Multiple Myeloma Patients
2/13/2024
Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") is pleased to announce that it has received the first patient sample for its clinical trial monitoring multiple myeloma ("MM") disease progression in post-treated patients.
-
Twist Bioscience Launches cfDNA Library Preparation Kit for Liquid Biopsy Applications
2/6/2024
Twist Bioscience Corporation today launched the cfDNA Library Preparation Kit to enable liquid biopsy research.
-
Telo Genomics Engages US Diagnostics Experts to Power Product Adoption in the US
1/30/2024
Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") is pleased to announce that it has engaged Trusted Health Advisors (THA)
-
Ultima Genomics Announces End of Early Access and Upcoming Launch of UG 100™
1/30/2024
Ultima Genomics, Inc today announced the launch and full commercial availability of the UG 100™ at the upcoming Advances in Genome Biology and Technology (AGBT) conference on February 5, 2024.
-
Angle PLC Announces Potential Utility in Precision Oncology
1/22/2024
ANGLE plc is pleased to announce the publication of a peer-reviewed paper in a special issue of the journal - "Current Issues in Molecular Biology" Special Issue: Advanced Solutions for Cancer Therapy.
-
Wren Laboratories Dr. Mark Kidd to speak at 2024 Precision Medicine World Conference
1/19/2024
The presentation will focus on the use of mRNA in Liquid Biopsies as a platform for precision diagnostics
-
CELLSEARCH® CTC count proves its clinical utility in guiding therapeutic strategy supporting patient care in HR+/HER2- metastatic breast cancer
1/16/2024
Menarini Silicon Biosystems, a pioneer of liquid biopsy and single-cell technologies, announced the recent publication of the STIC CTC trial data demonstrating the clinical utility of CTC count as an independent prognostic factor in advanced breast cancer.